Monte Rosa Therapeutics
GLUE
105 hedge funds and large institutions have $276M invested in Monte Rosa Therapeutics in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 23 increasing their positions, 44 reducing their positions, and 21 closing their positions.
100% more call options, than puts
Call options by funds: $413K | Put options by funds: $206K
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
1% more funds holding
Funds holding: 104 → 105 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.49% less ownership
Funds ownership: 99.26% → 96.77% (-2.5%)
35% less capital invested
Capital invested by funds: $423M → $276M (-$147M)
48% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$17.8M |
| 2 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$2.36M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$1.84M |
| 4 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$1.76M |
| 5 |
Millennium Management
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$11.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.36M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.77M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$3.09M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$2.95M |
GLUE Hedge Fund Activity: Q1 2025 in Review
105 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2025, worth a combined $276M — down 35% from $423M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GLUE positions and 21 closed out — a net gain of 1 holder — while 23 added to existing stakes and 44 trimmed.
The largest buyer was BVF Inc, adding an estimated $17.8M. The largest seller was Morgan Stanley, cutting an estimated $11.2M.
- 105 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2025, up from 104 in Q4 2024.
- Funds reported $276M of Monte Rosa Therapeutics stock for Q1 2025, down 35% quarter-over-quarter.
- 22 funds opened new Monte Rosa Therapeutics positions in Q1 2025 and 21 closed out, a net change of +1 holder.
- The largest Monte Rosa Therapeutics buyer in Q1 2025 was BVF Inc, an estimated $17.8M added.
- The largest Monte Rosa Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2025.